Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 9011

BillFederalHouseIn Committee
To amend the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services to establish a process to allow the holders of abbreviated new drug applications to make labeling changes to include new or updated safety-related information, and for other purposes.
About This Bill
Committee
Congress
117th (2021–2023)
Introduced
September 28, 2022
Cosponsors (0)
None
View PDF ↗

Summary

Highlight any text to annotate
Updated Drug Labeling for Patient Safety Act This bill allows generic drug manufacturers to revise labels with updated safety information that differs from the referenced brand-name drug.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.